<DOC>
	<DOCNO>NCT02893254</DOCNO>
	<brief_summary>Study efficacy safety IBI303 compare adalimumab adult patient ankylose spondylitis ( AS ) inadequate response intolerant one nonsteroidal anti-inflammatory drug ( NSAIDs )</brief_summary>
	<brief_title>Efficacy Safety IBI303 Adult Patients With Active Ankylosing Spondylitis</brief_title>
	<detailed_description>Adults patient active ankylose spondylitis ( AS ) randomize 1:1 ratio receive treatment adalimumab 40 mg every week ( eow ) IBI303 , give subcutaneously ( SC ) , 24-week double-blind ( DB ) phase . Randomized participant receive one SC injection appropriate DB study medication ( adalimumab 40 mg IBI303 ) Week 0 eow Week 22 . A follow-up visit occur 70 day ( Week 32 ) last dose study drug obtain information ongoing new adverse event ( AEs ) .</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>1 . Between 18 65 year age 2 . Fulfilled modify New York Criteria AS , active disease（as define by≥2 following : Bath AS Disease Activity Index ( BASDAI ) ≥4 ( 10cm VAS ) ; total back pain≥40 ( 100mm VAS ) ≥1 hour morning stiffness） 3 . No response , inadequate response , intolerant to≥1 NSAID least 4 week 4 . Participants regularly take DMARDs ( SSZ≤3g/day，MTX≤15mg/week ) part AS therapy require stable dose ≥28 day prior Baseline , require stable DMARDs dose accept oral folic acid therapy ( ≥5mg/week ) study period； 5 . Participants regularly take NSAIDs part AS therapy require stable dose ≥14 day prior Baseline , require stable dose study period； 6 . Glucocorticoid must withdraw least 4 week prior Baseline , allow study period . 7 . Total duration prior physical therapy least 2 week 8 . Traditional Chinese medicine AS must withdraw least 28 day prior Baseline , allow study period . 9 . Biological agent must withdraw : etanercept anakinra ( IL1 receptor antagonist ) least 4 week prior administration ; tocilizumab ( IL6 monoclonal antibody ) least 12 week prior administration ; biological agent 12 week 5 halflives ( whichever longer ) prior administration 10 . Male subject ' partner , female subject willing use adequate contraception admission clinical research center 5 month post dosing； 11 . To fully understand purpose study , understand pharmacological action study drug possible adverse reaction ; participant voluntary sign inform consent accord Declaration Helsinki 12 . Blood routine examination : hemoglobin ≥90g/L , WBC count ≥3.5×109/L , PLT count ≥100×109/L ; liver function examination : total bilirubin ( TBIL ) , direct bilirubin ( DBIL ) , aspartate transaminase ( AST ) alanine aminotransferase ( ALT ) ＜1.5×ULN ; kidney function examination：creatinine ( Cr ) ≤ULM , usea nitrogen ( BUN ) ≤1.25×ULN 1 . No response prior tumor necrosis factorα inhibitor treatment 2 . Use DMARD ( except sulfasalazine methotrexate ) within 4 week prior Baseline 3 . Use opioid analgesic ( methadone , morphine ) within 4 week prior Baseline 4 . Xray suggest total spinal ankylosis , sacroiliac joint fusion 5 . Patients moderate severe congestive heart failure（NYHA ） 6 . Has receive intraarticular joint injection ( ) , spinal paraspinal injection ( ) corticosteroid within 28 day prior Baseline 7 . Has undergone spinal surgery joint surgery within 2 month prior administration study drug 8 . Patients rheumatic disease immunodeficiency , include inflammatory bowel disease ( IBD ) , psoriasis , active uveitis 9 . Recent active chronic infection require antiinfective therapy , M.tuberculosis , Listeriosis , Histophasmosis 10 . Tuberculosis ( TB ) history , positive TSPOT test , chest radiograph suggest active TB 11 . Positive serology human immunodeficiency virus ( HIV ) antibody 12 . Positive serology hepatitis C virus antibody 13 . Active chronic HBV infection , positive hepatitis B virus surface antigen 14 . Malignancy history ≤5 years（except successfully treat cutaneous squamous cell carcinoma , basal cell carcinoma , localized cervical carcinoma situ , breast ductal carcinoma situ） 15 . History relevant allergy/hypersensitivity ( include allergy study medication excipients ) 16 . Prior recent central nervous system demyelinate disease multiple sclerosis 17 . Use live vaccine within 3 month prior Baseline 18 . Pregnant breastfeed woman 19 . Suspected confirm drug/alcohol use 20 . Participation another interventional trial within 3 month prior administration 21 . Subjects serious psychiatric nervous system disease , patient difficulty inform consent AE presentation , illiterate patient 22 . Subjects unable complete study , may able comply requirement study , judge investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>ankylose spondylitis , tumor necrosis factor-α inhibitor</keyword>
</DOC>